ForPatients
by Roche

Spinal Muscular Atrophy (SMA)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

Trial Status	Trial Runs In	Trial Identifier
Completed	16 Countries	NCT02908685 2016-000750-35 BP39055

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part (Part 2) of Risdiplam for 24 months.

Hoffmann-La Roche	Phase 2
Sponsor	Phase

NCT02908685 2016-000750-35 BP39055
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 2 Years & <= 25 Years	No